Mezzasalma Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Mezzasalma Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56M	Hold	2,500	–	–	0.31%	56
2026 Q1	$1.93M	Hold	2,500	–	–	0.49%	43
2025 Q4	$1.94M	Hold	2,500	–	–	0.47%	49
2025 Q3	$1.41M	Hold	2,500	–	–	0.36%	49
2025 Q2	$1.31M	Hold	2,500	–	–	0.39%	44
2025 Q1	$1.59M	Hold	2,500	–	–	0.55%	38
2024 Q4	$1.78M	Hold	2,500	–	–	0.57%	34
2024 Q3	$2.63M	Hold	2,500	–	–	1.04%	28
2024 Q2	$2.63M	Sell	2,500 -33	-1%	-$32K	1.13%	27
2024 Q1	$2.44M	Buy	2,533 +33	+1%	+$31.4K	1.15%	19
2023 Q4	$2.2M	Sell	2,500 -10	-0.4%	-$8.23K	1.2%	18
2023 Q3	$2.07M	Hold	2,510	–	–	1.27%	19
2023 Q2	$1.8M	Buy	2,510 +10	+0.4%	+$7.71K	1.09%	21
2023 Q1	$2.05M	Hold	2,500	–	–	1.45%	19
2022 Q4	$1.8M	Sell	2,500 -9	-0.4%	-$6.64K	1.57%	18
2022 Q3	$1.73M	Buy	2,509 +9	+0.4%	+$5.67K	1.37%	16
2022 Q2	$1.48M	Hold	2,500	–	–	1.25%	17
2022 Q1	$1.75M	Hold	2,500	–	–	1.09%	19
2021 Q4	$1.58M	Hold	2,500	–	–	0.85%	25
2021 Q3	$1.51M	Hold	2,500	–	–	0.85%	26
2021 Q2	$1.4M	Buy	2,500 +500	+25%	+$253K	0.77%	30
2021 Q1	$946K	Buy	2,000 +1,000	+100%	+$487K	0.61%	36
2020 Q4	$483K	Buy	+1,000	New	+$540K	0.31%	47

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Mezzasalma Advisors's REGN Position: Q2 2026 in Review

Mezzasalma Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 2,500 shares worth $1.56M. The position accounts for 0.31% of the portfolio, ranked #56.

Mezzasalma Advisors first reported a position in REGN in Q4 2020 and has held it in 23 quarters since. The position peaked at $2.63M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Mezzasalma Advisors held 2,500 shares of Regeneron Pharmaceuticals worth $1.56M as of Q2 2026.
Mezzasalma Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.31% of Mezzasalma Advisors's portfolio in Q2 2026, its #56 holding.
Mezzasalma Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
Mezzasalma Advisors's Regeneron Pharmaceuticals position peaked at $2.63M in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Mezzasalma Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.